Scholarlink

Background <p>Capsular contracture is a major complication of breast reconstruction with silicone implants, affecting patients' quality of life due to pain and esthetic concerns. Capsular contracture is considered to result from an excessive fibrous foreign body reaction to the implant, but its precise mechanism remains unclear, and no effective preventative approaches have been established. Previously, we reported that transdermal application of 4-hydroxytamoxifen (4-OH TAM), an active metabolite of TAM, inhibited capsule formation in a mouse model. Building on this, we examined whether a sustained-release system, directly delivering 4-OH TAM around the silicone implant, could achieve a similar effect with clinical applications in mind.</p> Methods <p>Fifty-one female ICR mice were divided into three groups: non-treated control (NT), 0.1&#xa0;mg 4-OH TAM (0.1mg_TAM), and 1.0&#xa0;mg 4-OH TAM (1.0mg_TAM). A silicone implant was inserted subcutaneously on the back of each mouse, with a silk elastin sponge impregnated with 4-OH TAM placed on top as a sustained-release system. After four weeks, capsule formation was evaluated by measuring capsule thickness, fibrillar collagen density, and chronic inflammation (CD45R).</p> Results <p>The 1.0mg_TAM group showed a significantly reduced capsule thickness compared to the NT group (<i>p</i> = 0.048). Although no statistical significance was observed, a decreasing trend was noted in fibrillar collagen density and CD45R-positive cell infiltration in the 1.0mg_TAM group (<i>p</i> = 0.175 and <i>p</i> = 0.260, respectively).</p> Conclusion <p>We demonstrated that sustained-release administration of 4-OH TAM effectively suppresses capsule formation. Further investigations are required to explore its potential for clinical application.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Sustained-release of 4-hydroxytamoxifen inhibits capsular contracture after breast implant placement in a mouse model

  • 期刊论文

  • 发表日期：

    2025年8月22日

查看全文
  • Nozomi Matsumoto,
  • Masako Muguruma,
  • Yoshiya Horimoto,
  • Miki Okazaki,
  • Mariko Asaoka,
  • Takako Komiya,
  • Eiichi Sato,
  • Utako Yokoyama,
  • Hajime Matsumura,
  • Takashi Ishikawa

摘要

Background

Capsular contracture is a major complication of breast reconstruction with silicone implants, affecting patients' quality of life due to pain and esthetic concerns. Capsular contracture is considered to result from an excessive fibrous foreign body reaction to the implant, but its precise mechanism remains unclear, and no effective preventative approaches have been established. Previously, we reported that transdermal application of 4-hydroxytamoxifen (4-OH TAM), an active metabolite of TAM, inhibited capsule formation in a mouse model. Building on this, we examined whether a sustained-release system, directly delivering 4-OH TAM around the silicone implant, could achieve a similar effect with clinical applications in mind.

Methods

Fifty-one female ICR mice were divided into three groups: non-treated control (NT), 0.1 mg 4-OH TAM (0.1mg_TAM), and 1.0 mg 4-OH TAM (1.0mg_TAM). A silicone implant was inserted subcutaneously on the back of each mouse, with a silk elastin sponge impregnated with 4-OH TAM placed on top as a sustained-release system. After four weeks, capsule formation was evaluated by measuring capsule thickness, fibrillar collagen density, and chronic inflammation (CD45R).

Results

The 1.0mg_TAM group showed a significantly reduced capsule thickness compared to the NT group (p = 0.048). Although no statistical significance was observed, a decreasing trend was noted in fibrillar collagen density and CD45R-positive cell infiltration in the 1.0mg_TAM group (p = 0.175 and p = 0.260, respectively).

Conclusion

We demonstrated that sustained-release administration of 4-OH TAM effectively suppresses capsule formation. Further investigations are required to explore its potential for clinical application.